# Atypical Antipsychotics in Improvement of Quality of Life in Bipolar Disorder

> **NCT00745966** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1000 (estimated)

## Conditions studied

- Naturalistic
- Observational

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00745966
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2008-09
- **Final completion:** —
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2008-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00745966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00745966, "Atypical Antipsychotics in Improvement of Quality of Life in Bipolar Disorder". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00745966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*